Ascendis Pharma A/S American Depositary Shares (ASND)
Company News
BioMarin Pharmaceutical reported strong Q4 earnings, beating consensus estimates for both EPS and revenue. The company provided upbeat 2025 guidance, expecting sales of $3.1-$3.2 billion and EPS of $4.20-$4.40.
Ascendis Pharma announced the pricing of a $300 million public offering of 2 million American Depositary Shares at $150 per share. The company plans to use the proceeds to support commercial activities, clinical development, and general corporate purposes.
Ascendis Pharma, a biotech company, reported a revenue miss and reduced guidance for its key product Skytrofa, leading to an over 11% drop in its stock price.
The FDA is expected to make several landmark decisions in Q3, including approvals for treatments for schizophrenia, PTSD, and liver disease. These decisions could be impacted by recent biotechnology acquisitions.